Deep learning to predict bevacizumab response in liver metastasis
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether a computer-based tool (deep learning) can predict how well the drug bevacizumab works for people with colorectal cancer that has spread only to the liver. The goal is to help doctors tailor treatment more precisely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread only to your liver (no other organs).
- Your tumor has a RAS mutation and does not have a BRAF V600E mutation.
- You have not yet had treatment (systemic therapy or surgery) for the metastatic disease.
- You have a PET/CT scan and colonoscopy biopsy samples available from before treatment.
- You are in good physical condition (ECOG 0-1) and expected to live more than 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a treatment approach for colorectal cancer that cannot be removed with surgery at first but has spread only to the liver. It is intended for people whose tumor is RAS/BRAF “wild-type” and who are well enough to do daily activities, to see if the treatment can control the cancer better.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination treatment that uses heat or cold (ablation) to destroy liver tumors along with medicines that boost your immune system to fight cancer. It is for people whose colorectal cancer has spread to the liver and who could not have surgery, or whose first treatment stopped working.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.